E-LIB Suche - Ergebnisse für: Foch, Caroline

1

Overall survival with cetuximab every-2-weeks versus standa..:

Kasper, Stefan ; Foch, Caroline ; Esser, Regina...
European Journal of Cancer. 180 (2023) - p. 85-88 , 2023

2

Risk of cancer with immunosuppressants compared to immunomo..:

Bosco‐Lévy, Pauline ; Boutmy, Emmanuelle ; Guiard, Estelle...
Pharmacoepidemiology and Drug Safety. 32 (2023) 12 - p. 1421-1430 , 2023

Link: https://doi.org/10.1002/..

3

Metformin in pregnancy and risk of abnormal growth outcomes..:

Brand, Kerstin MG ; Thoren, Robyn ; Sõnajalg, Jaak...
BMJ Open Diabetes Research & Care. 10 (2022) 6 - p. e003056 , 2022

Link: https://doi.org/10.1136/..

4

Real-World Effectiveness of Beta-Blockers versus Other Anti..:

Foch, Caroline ; Allignol, Arthur ; Hostalek, Ulrike...
International Journal of Clinical Practice. 2022 (2022) - p. 1-11 , 2022

Link: https://doi.org/10.1155/..

5

Incidence of malignancies in patients with multiple scleros..:

Kuiper, Josephina G. ; Overbeek, Jetty A. ; Foch, Caroline..
Journal of Clinical Neuroscience. 103 (2022) - p. 49-55 , 2022

Link: https://doi.org/10.1016/..

6

Quality and Characteristics of 4241 Case Reports of Lactic ..:

Brand, Kerstin MG ; Schlachter, Judith ; Foch, Caroline.
Therapeutics and Clinical Risk Management. 18 (2022) - p. 1037-1047 , 2022

Link: https://doi.org/10.2147/..

7

An anchored simulated treatment comparison of uptitration o..:

Foch, Caroline ; Feifel, Jan ; Gottwald-Hostalek, Ulrike
Current Medical Research and Opinion. 38 (2022) 4 - p. 587-593 , 2022

Link: https://doi.org/10.1080/..

8

Metformin in pregnancy and risk of adverse long-term outcom..:

Brand, Kerstin M G ; Saarelainen, Laura ; Sonajalg, Jaak...
BMJ Open Diabetes Research & Care. 10 (2022) 1 - p. e002363 , 2022

Link: https://doi.org/10.1136/..

9

Incidence and risk of cancer among multiple sclerosis patie..:

Bosco‐Lévy, Pauline ; Foch, Caroline ; Grelaud, Angela...
European Journal of Neurology. 29 (2022) 4 - p. 1091-1099 , 2022

Link: https://doi.org/10.1111/..

10

Incidence of malignancy in multiple sclerosis: A cohort stu..:

Nørgaard, Mette ; Veres, Katalin ; Sellebjerg, Finn T...
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 7 (2021) 4 - p. 205521732110539 , 2021

Link: https://doi.org/10.1177/..

11

Noninferiority of cetuximab every-2-weeks versus standard o..:

Kasper, Stefan ; Foch, Caroline ; Messinger, Diethelm...
European Journal of Cancer. 144 (2021) - p. 291-301 , 2021

Link: https://doi.org/10.1016/..

12

Corrigendum to "Subcutaneous interferon beta-1a 22/44 µg de..:

Rollot, Fabien ; Foch, Caroline ; Laplaud, David...
Multiple Sclerosis and Related Disorders. , 2020

Link: https://doi.org/10.1016/..

13

L'interféron bêta-1a sous-cutané 22/44 μg démontre une effi..:

Rollot, Fabien ; Foch, Caroline ; Laplaud, David-Axel...
Revue Neurologique. 176 (2020) - p. S79-S80 , 2020

Link: https://doi.org/10.1016/..

14

Dynamic Cohorts in Multiple Sclerosis: A Proactive Approach..:

Sabidó, Meritxell ; Batech, Michael ; Foch, Caroline..
Neurology. 94 (2020) 15_supplement - p. , 2020

Link: https://doi.org/10.1212/..

15

Subcutaneous Interferon Beta-1a 22/44 mg Demonstrates Compa..:

Rollot, Fabien ; Foch, Caroline ; Laplaud, David...
Multiple Sclerosis and Related Disorders. 37 (2020) - p. 101598 , 2020

Link: https://doi.org/10.1016/..